The global oral solid dosage manufacturing market, valued at USD 599 billion in 2025, is projected to reach USD 623 billion in 2026 and USD 861 billion by 2035, with a CAGR of 3.7% during the forecast period 2026 to 2035. Based on the type of packaging, blisters are likely to occupy the largest share of the market in 2035. Based on company size, large companies are anticipated to hold the highest market share (close to 75%) in 2026. In August 2025, Piramal Pharma Solutions announced the collabor...

The global biologics API market size, valued at USD 70.4 billion in 2025, is projected to reach USD 78.4 billion in 2026 and USD 153.8 billion by 2035, representing a CAGR of 8% during the forecast period, 2026 to 2035. Several large biopharmaceutical players, such as Novartis, Pfizer, Roche and Eli Lilly are supporting the active pharmaceutical ingredient manufacturing in their in-house API manufacturing facilities for the efficient production of various biologics. In the future, hybrid manufac...

The global next generation RNA therapeutics market, is projected to reach USD 0.1 billion in 2029 and USD 2.7 billion by 2035, representing a CAGR of 63.1% during the forecast period 2029 to 2035. The US FDA Biologics License Application (BLA) Pathway: The US FDA regulates RNA therapeutics and vaccines as biologics under the Center for Biologics Evaluation and Research (CBER). In June 2025, the Data 2 Reality (D2R) initiative allocated USD 400,000 to fund pioneering projects in next-generation R...

The global cancer biologics market size, valued at USD 189 billion in 2025, is projected to reach USD 210 billion in 2026 and USD 442 billion by 2035, with a CAGR of 8.6% during the forecast period 2026 to 2035. In the past few years, drug-based interventions (including biologics and small molecules) have observed a rapidly expanding pipeline for various types of cancer. The increased focus on personalized cancer biologics therapy market has garnered the interest of several pharmaceutical compan...

The global RNA extraction and RNA purification market size is estimated to reach $5.6 billion by 2035. Though these kits offer various significances, there are several limitations associated with the automation of RNA extraction, such as sample type compatibility, RNA integrity, yield purity, and inaccurate representation of gene expression. To address these concerns, extensive research has been carried out by key players to identify / develop strategies to improve RNA extraction and RNA purific...

The ADC cytotoxic payloads and warheads market, valued at USD 381.3 million in 2025, is projected to reach USD 469.3 million in 2026 and USD 720.2 million by 2035, representing a CAGR of 4.9% during the forecast period 2026 to 2035. According to the ADC cytotoxic payloads and warheads market forecast, the commercial ADCs sub-segment dominates the market (90%), driven by the increased demand for commercialized ADCs owing to their efficacy and safety profile. In 2035, Europe’s ADC cytotoxic payl...

The global complement inhibitors market size, valued at USD 12.56 billion in 2025, is projected to reach USD 14.30 billion in 2026 and USD 28.65 billion by 2035, with a CAGR of 8% during the forecast period 2026 to 2035. In terms of geographical regions, North America is holding 68% of the complement inhibitors market share due to the growing research, favorable regulatory guidelines, and a strong presence of top complement inhibitors companies. In January 2025, Teva and Samsung Bioepis enter in...

The global pharma cloud services market, valued at USD 10.8 billion in 2025, is projected to reach USD 13.0 billion in 2026 and USD 42.9 billion by 2035, representing a CAGR of 14.2% during the forecast period 2026 to 2035. In terms of area of application, drug discovery holds the highest share (nearly 50%) of the market. In terms of end user, pharmaceutical and life science companies hold the highest share (65%) of the current market. In terms of geographical regions, North America holds the hi...

The LNP patent landscape features more than 2,500 patents covering a wide spectrum of innovations in this field. It is worth noting that (nearly 40%) drug formulations are poorly soluble in aqueous media, limiting drug delivery efficiency, thereby increasing demand for advanced formulation technologies like lipid nanoparticles (LNPs). Presently, researchers are evaluating approximately 70% of BCS class II drugs across different clinical stages, providing a wide opportunity for the use of LNPs in...

The global AI virtual companions market, valued at USD 34 billion in 2025, is projected to reach USD 44 billion in 2026 and USD 361 billion by 2035, with a CAGR of 26.4% during the forecast period 2026 to 2035. With regards to companion type, the text-based AI companions segment dominates the market by securing nearly 45% of the overall revenue share. In terms of application area, the social interaction and companionship segment holds the largest share of the market. North America region current...

The global biosimilars market, valued at USD 28.0 billion in 2025, is projected to reach USD 32.3 billion in 2026 and USD 130.1 billion by 2035, representing a CAGR of 16.7% during the forecast period 2026 to 2035. With respect to distribution channel, hospital pharmacies dominate (nearly 45%) the current market. In terms of geographical regions, currently, Europe holds the highest market share (over 50%). The most recent advancement in the biologics and biosimilars market has been the launch of...

The fill finish pharmaceutical contract manufacturing market, valued at USD 7.2 billion in 2024, is project to reach USD 7.5 billion in 2025 and USD 12.1 billion by 2035, representing a CAGR of 4.8% during the forecast period 2025 to 2035. Fill finish of small molecules is final step in the downstream processing of a product, wherein the desired formulation is mixed with the necessary excipients and stabilizers, followed by filling the purified bulk formulation into the pre-sterilized packaging...

The global nucleic acid isolation and purification market size, valued at USD 5.41 billion in 2025, is projected to reach USD 5.75 billion in 2026 and USD 10.52 billion by 2035, representing a CAGR of 6.9% during the forecast period 2026 to 2035. The global market for nucleic acid isolation and purification products is rapidly growing, driven by the widespread adoption of next generation sequencing technologies, increasing interest in molecular biology and growing R&D investments for discovery a...

The global molecukar diagnostics market, valued at USD 17 billion in 2025, is projected to reach USD 18 billion in 2026 and USD 31 billion by 2035, with a 6.4% CAGR during the forecast period 2026 to 2035.Molecular diagnostic tests refer to tests designed to detect specific sequences in human genomic samples, such as DNA or RNA, in order to diagnose a particular disease. Further, such tests also aim to identify single nucleotide polymorphisms, deletions, rearrangements, and insertions in the...

The sleep apnea devices market is estimated to be worth $13.5 billion in 2024 and is anticipated to grow at a CAGR of 4.61% during the forecast period from 2023 to 2035. Sleep apnea, used interchangeably with sleep apnoea, is one of the serious sleep disorders characterized by repeated start or stop in breathing during sleep. These interruptions in sleep can last up to several minutes. Sleep apnea can be broadly categorized into three types, obstructive sleep apnea, central sleep apnea and compl...

The global pet at-home diagnostic tests market, valued at USD 80 million in 2024, is projected to reach USD 85 million in 2025 and USD 138 million by 2035, representing a CAGR of 5.0% during the forecast period 2025 to 2035. In terms of type of animals, the dogs segment holds the highest share (nearly 60%) of the market. With respect to type of sample, the blood sample segment dominates the current market. Based on the distribution channel, e-commerce segment is capturing largest share of the ma...

The global immune checkpoint inhibitors market, valued at USD 75 billion in 2025, is projected to reach USD 82 billion in 2026 and USD 146 billion by 2035, with a 6.6% CAGR during the forecast period 2026 to 2035. John E. Dick (American Association for Cancer Research Hematologic Malignancies Working Group Committee Member) says that ‘It’s become clear that clonal hematopoiesis is influencing how immune checkpoint inhibitor therapy works in certain subsets of patients. the lung cancer segmen...

The global plasma fractionation market valued at $ 5.3 billion in 2025, is project to reach $ 5.8 billion in 2026 and $ 12.7 billion by 2035, representing a higher CAGR of 9.1% during the forecast period 2026 to 2035. In terms of type of company, the in-house manufacturers’ segment holds the highest share of the market.In terms of scale of operation, the commercial segment dominates the global market. Based on the type of plasma-derived therapeutic products manufactured, immunoglobulins segme...

Diabetes is a chronic disease growing at an alarming rate across the globe. Over 382 million people are estimated to be currently suffering from the disease; the number is likely to increase to 592 million by 2035. With a very high prevalence, especially in some regions such as China and India, an increasing proportion of diabetic patients are likely to benefit from more efficient and accurate diagnostic tests in the future. HbA1c, adapted for clinical testing to monitor diabetes in 1990s, is on...

The human microbiome market, valued at USD 0.63 billion in 2025, is projected to grow to USD 0.85 billion in 2026 and USD 3.27 billion by 2035, representing a CAGR of 16% during the forecast period. It is worth mentioning that, owing to the rising interest, a number of start-ups / small firms have established in the past few years and the contributions of big pharma players have fueled the overall growth in human microbiome market. Driven by increasing prevalence of disease indications, promisin...